Exact Sciences Corp. (EXAS), a provider of cancer screening and diagnostic tests, has received FDA approval for the Cologuard Plus test, the company's next-generation multitarget stool DNA test.
The Cologuard Plus test is approved for adults ages 45 and older who are at average risk for colorectal cancer and will be launched in 2025. The new version will minimize unnecessary follow-up colonoscopies by reducing the likelihood of a false-positive screening test, according to the company.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.